Cargando…

Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis

BACKGROUND: Human umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent progenitor cells representing an attractive therapeutic tool for tissue damage and inflammation owing to their unique immunomodulatory properties. This study was designed to determine the protective effects and underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mengting, He, Jing, Zheng, Shuo, Zhang, Ke, Ouyang, Yu, Zhang, Yaqi, Li, Changyong, Wu, Dongcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640895/
https://www.ncbi.nlm.nih.gov/pubmed/34926659
http://dx.doi.org/10.21037/atm-21-2885
_version_ 1784609404161622016
author Liu, Mengting
He, Jing
Zheng, Shuo
Zhang, Ke
Ouyang, Yu
Zhang, Yaqi
Li, Changyong
Wu, Dongcheng
author_facet Liu, Mengting
He, Jing
Zheng, Shuo
Zhang, Ke
Ouyang, Yu
Zhang, Yaqi
Li, Changyong
Wu, Dongcheng
author_sort Liu, Mengting
collection PubMed
description BACKGROUND: Human umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent progenitor cells representing an attractive therapeutic tool for tissue damage and inflammation owing to their unique immunomodulatory properties. This study was designed to determine the protective effects and underlying mechanisms of UC-MSCs on acute liver failure (ALF). METHODS: ALF was induced in mice by intraperitoneal injection of D-galactosamine (D-GalN) and lipopolysaccharide (LPS). Mice were intravenously injected with 1×10(6) UC-MSCs one hour before or six hours after D-GalN/LPS injection. Liver function was valued by serum biochemical parameters and hematoxylin-eosin staining. Inflammatory cytokine and chemokine levels were measured by real-time PCR, and inflammatory cells infiltration was observed by immunofluorescence staining. Hepatocyte apoptosis and pyroptosis related proteins were detected by western blot. Murine macrophage Raw264.7 in the presentation of LPS was treated with the UC-MSCs condition medium (UC-MSCs-CM), and then the levels of inflammatory cytokines and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in Raw264.7 were measured. RESULTS: UC-MSCs significantly reduced the mortality, decreased serum alanine aminotransferase and aspartate aminotransferase levels, and improved the pathological damage. Moreover, UC-MSCs inhibited inflammatory cytokine and chemokine levels, especially TNF-α, interleukins-6 (IL-6), IL-1β, monocyte chemoattractant protein (MCP-1), CC-chemokines ligand 2 (CCL2), C-X-C motif ligand 2 (CXCL2), and reduced macrophage, neutrophil and T lymphocyte infiltration into the liver tissue. UC-MSCs also attenuated hepatocyte apoptosis, as evidenced by decreased TUNEL positive cells, increased Bcl-xl/Bax protein ratio and downregulated cleaved caspase 3 levels. NLRP3 inflammasome activation, IL-1β maturation and cleaved caspase1 were suppressed by UC-MSC administration. Furthermore, the UC-MSCs-CM reduced the levels of inflammatory cytokines and the activation of NLRP3 inflammasome in Raw264.7. CONCLUSIONS: Our results demonstrated that UC-MSCs exerted therapeutic effects on ALF by inhibiting apoptosis, inflammation, and pyroptosis.
format Online
Article
Text
id pubmed-8640895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-86408952021-12-16 Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis Liu, Mengting He, Jing Zheng, Shuo Zhang, Ke Ouyang, Yu Zhang, Yaqi Li, Changyong Wu, Dongcheng Ann Transl Med Original Article BACKGROUND: Human umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent progenitor cells representing an attractive therapeutic tool for tissue damage and inflammation owing to their unique immunomodulatory properties. This study was designed to determine the protective effects and underlying mechanisms of UC-MSCs on acute liver failure (ALF). METHODS: ALF was induced in mice by intraperitoneal injection of D-galactosamine (D-GalN) and lipopolysaccharide (LPS). Mice were intravenously injected with 1×10(6) UC-MSCs one hour before or six hours after D-GalN/LPS injection. Liver function was valued by serum biochemical parameters and hematoxylin-eosin staining. Inflammatory cytokine and chemokine levels were measured by real-time PCR, and inflammatory cells infiltration was observed by immunofluorescence staining. Hepatocyte apoptosis and pyroptosis related proteins were detected by western blot. Murine macrophage Raw264.7 in the presentation of LPS was treated with the UC-MSCs condition medium (UC-MSCs-CM), and then the levels of inflammatory cytokines and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in Raw264.7 were measured. RESULTS: UC-MSCs significantly reduced the mortality, decreased serum alanine aminotransferase and aspartate aminotransferase levels, and improved the pathological damage. Moreover, UC-MSCs inhibited inflammatory cytokine and chemokine levels, especially TNF-α, interleukins-6 (IL-6), IL-1β, monocyte chemoattractant protein (MCP-1), CC-chemokines ligand 2 (CCL2), C-X-C motif ligand 2 (CXCL2), and reduced macrophage, neutrophil and T lymphocyte infiltration into the liver tissue. UC-MSCs also attenuated hepatocyte apoptosis, as evidenced by decreased TUNEL positive cells, increased Bcl-xl/Bax protein ratio and downregulated cleaved caspase 3 levels. NLRP3 inflammasome activation, IL-1β maturation and cleaved caspase1 were suppressed by UC-MSC administration. Furthermore, the UC-MSCs-CM reduced the levels of inflammatory cytokines and the activation of NLRP3 inflammasome in Raw264.7. CONCLUSIONS: Our results demonstrated that UC-MSCs exerted therapeutic effects on ALF by inhibiting apoptosis, inflammation, and pyroptosis. AME Publishing Company 2021-11 /pmc/articles/PMC8640895/ /pubmed/34926659 http://dx.doi.org/10.21037/atm-21-2885 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Liu, Mengting
He, Jing
Zheng, Shuo
Zhang, Ke
Ouyang, Yu
Zhang, Yaqi
Li, Changyong
Wu, Dongcheng
Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title_full Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title_fullStr Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title_full_unstemmed Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title_short Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
title_sort human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640895/
https://www.ncbi.nlm.nih.gov/pubmed/34926659
http://dx.doi.org/10.21037/atm-21-2885
work_keys_str_mv AT liumengting humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT hejing humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT zhengshuo humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT zhangke humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT ouyangyu humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT zhangyaqi humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT lichangyong humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis
AT wudongcheng humanumbilicalcordmesenchymalstemcellsameliorateacuteliverfailurebyinhibitingapoptosisinflammationandpyroptosis